Omalizumab, recombinant humanized monoclonal antibody anti-lgE - New fields of studies on the therapeutic indications;Omalizumab, rekombinowane humanizowane monoklonalne przeciwciało anty-lgE -nowe kierunki badań nad zastosowaniem klinicznym leku

Pneumonologia i Alergologia Polska

Volumn 77, Issue 1, 2009, Pages 43-51

  Kupryś Lipińska, Izabela ^a   Kuna, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Allergic rhinitis; Atopic dermatitis; Atopic diseases; Omalizumab; Urticaria

Indexed keywords

ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY; OMALIZUMAB;

ASTHMA; BLOOD; CLINICAL TRIAL; EUROPEAN UNION; HAY FEVER; HUMAN; IMMUNOLOGY; PERENNIAL RHINITIS; RESPIRATORY TRACT ALLERGY; REVIEW; UNITED STATES;

ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS AS TOPIC; EUROPEAN UNION; HUMANS; IMMUNOGLOBULIN E; RESPIRATORY HYPERSENSITIVITY; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; UNITED STATES;

EID: 67649213946     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Kupryś I., Kuna P. Regulation of immunoglobulin E synthesis. Postepy Hig. Med. Dosw. 1997; 51: 651-682.
2. Bozelka B.E., McCants M.L., Salvaggio J.E., Lehrer S.B. IgE isotype suppression in anti-epsilon-treated mice. Immunology 1982; 46: 527-532.
3. Hamelmann E. The rationale for treating allergic asthma with antiIgE. Eur. Respir. Rev. 2007; 16: 61-66.
4. Bobrowska M., Stelmach I. Therapeutic possibilities and clinical effects of IgE level modulation in allergic diseases. Pneumonol. Alergol. Pol. 2004; 72: 70-74.
5. Sarinho E., Cruz A.A. Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases. J. Pediatr. (Rio. J.) 2006; 82 (supl. 5): 127-132.
6. Djukanović R., Wilson S.J., Kraft M. i wsp. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 2004; 170: 583-593.
7. MacGlashan D.W. Jr, Bochner B.S., Adelman D.C i wsp. Down-regulatlon of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 1997; 158: 1438-1445.
8. Lin H., Boesel K.M., Griffith D.T. i wsp. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J. Allergy Clin. Immunol. 2004; 113: 297-302.
9. Chang T.W., Shiung Y.Y. Anti-IgE as a mast cell-stabilizing therapeutic agent. J. Allergy Clin. Immunol. 2006; 117: 1203-1212.
10. Saini S.S., MacGlashan D.W. Jr, Sterbinsky S.A. i wsp. Down-regulation of human basophil IgE and FceRI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J. Immunol. 1999; 162: 5624-5630.
11. Prassin C., Griffith D.T., Boesel K.M., Lin H., Foster B., Casale T.B. Omalizumab treatment downregulates dendritic cell FcεRI expression. J. Allergy Clin. Immunol. 2003; 112: 1147-1154.
12. Noga O., Hanf G., Kunkel G., Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int. Arch. Allergy Immunol. 2007; 146: 66-70.
13. Noga O., Hanf G., Brachmann I. i wsp. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J. Allergy Clin. Immunol. 2006; 117 1493-1499.
14. www.novartis.pl. Charakterystyka produktu leczniczego Xolair
15. Bousquet J., Cabrera P., Berkman N. i wsp. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302-308.
16. Walker S., Montell M., Phelan K., Lasserson T.J., Walters E.H. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2006; CD003559.
17. Chipps B., Buhl R., Beeh K.M., Fox H., Thomas K., Reisner C Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr. Med. Res. Opin. 2006; 22: 2201-2208.
18. Casale T.B., Condemi J., LaForce C. i wsp. Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286: 2956-2967.
19. Okubo K., Ogino S., Nagakura T., Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol. Int. 2006; 55: 379-386.
20. Chervinsky P., Casale T., Townley R. i wsp. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis, Ann. Allergy Asthma Immunol. 2003; 91: 160-167.
21. Vignola A.M., Humbert M., Bousquet J. i wsp. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59: 709-717.
22. Krathen R.A., Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J. Am. Acad. Dermatol. 2005; 53: 338-340.
23. Lane J.E., Cheyney J.M., Lane T.N., Kent D.E., Cohen D.J. Treatment of recalcitrant atopic dermatitis with omalizumab. J. Am. Acad. Dermatol. 2006; 54: 68-72.
24. Vigo P.G., Girgis K.R., Pfuetze B.L., Critchlow M.E., Fisher J., Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J. Am. Acad. Dermatol. 2006; 55: 168-170.
25. Forman S.B., Garrett A.B. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcεRI. Cutis 2007; 80: 38-40.
26. Belloni B., Ziai M., Lim A. i wsp. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J. Allergy Clin. Immunol. 2007; 120: 1223-1225.
27. Spector S.L., Tan R.A. Effect of omalizumab on patients with chronic urticaria. Ann. Allergy Asthma Immunol. 2007; 99: 190-193.
28. Boyce J.A. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J. Allergy Clin. Immunol. 2006; 117: 1415-1418.
29. Metz M., Bergmann P., Zuberbier T., Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 247-249.
30. Sands M.F., Blume J.W., Schwartz S.A. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J. Allergy Clin. Immunol. 2007; 120: 979-981.
31. Leung D.Y., Sampson H.A., Yunginger J.W. i wsp. Avon Longitudinal Study of Parents and Children Study Team. Effect, of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med. 2003; 348:986-993.
32. Chang T.W., Wu P.C., Hsu C.L., Hung A.F. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv. Immunol. 2007; 93: 63-119.
33. Leynadier F., Doudou O., Gaouar H. i wsp. Effect of omalizumab in health care workers with occupational latex allergy. J. Allergy Clin. Immunol. 2004; 113: 360-361.
34. van der Ent C.K., Hoekstra H., Rijkers G.T. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant antiIgE antibody.Thorax 2007; 62: 276-277.
35. Carter M.C., Robyn J.A., Bressler P.B., Walker J.C., Shapiro G.G., Metcalfe D.D. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J. Allergy Clin. Immunol. 2007; 119: 1550-1551.
36. Giavina-Bianchi P., Giavina-Bianchi M., Agondi R., Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int. Arch. Allergy Immunol. 2007; 144:155-158.
37. Winchester D.E., Jacob A., Murphy T. Omalizumab for asthma. N. Engl. J. Med. 2006; 355: 1281-1282.
38. Ruppert A.M., Averous G., Stanciu D. i wsp. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J. Allergy Clin. Immunol. 2008; 121: 253-254.
39. Bargagli E., Madioni C., Olivieri C., Penza F., Rottoli P. Churg-Strauss vasculitis in a patient treated with omalizumab. J. Asthma 2008; 45: 115-116.
40. Lee J., Doggweiler-Wiygul R., Kim S., Hill B.D., Yoo T.J. Is interstitial cystitis an allergic disorder? A case of interstitial cystitis treated successfully with anti-IgE. Int. J. Urol. 2006; 13: 631-634.
41. Kuehr J., Brauburger J., Zielen S. i wsp. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2002; 109: 274-280.
42. Rolinck-Werninghaus C., Hamelmann E., Keil T. i wsp. The coseasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergie children. Allergy 2004; 59: 973-979.
43. Kopp M.V., Brauburger J., Riedinger F. i wsp. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2002; 110: 728-735.
44. Kopp M.V., Mayatepek E., Engels E. i wsp. Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab). Pediatr. Allergy Immunol. 2003; 14: 401-404.
45. Bez C., Schubert R., Kopp M. i wsp. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin. Exp. Allergy 2004; 34: 1079-1085.
46. Kopp M.V., Stenglein S., Kamin W. i wsp. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr. Allergy Immunol. 2007; 18: 523-527.
47. Casale T.B., Busse W.W., Kline J.N. i wsp. Omalizumab pretreatment decreases acute reactions after rush immunotherapy far ragweed-induced seasonal allergie rhinitis. J. Allergy Clin. Immunol. 2006; 117: 134-140.
48. Klunker S., Saggar L.R., Seyfert-Margolis V. i wsp. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J. Allergy Clin. Immunol. 2007; 120: 688-695.
49. Schulze J., Rose M., Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007; 62: 963-964.
50. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63: 376-378.
51. Soriano Gomis V., Gonzalez Delgado P., Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J. Investig. Allergol Clin. Immunol. 2008; 18: 225-226.
52. Limb S.L., Starke P.R., Lee C.E., Chowdhury B.A. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J. Allergy Clin. Immunol. 2007; 120: 1378-1381.
53. Cox L., Platts-Mills T.A., Finegold I. i wsp. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J. Allergy Clin. Immunol. 2007; 120: 1373-1377.
54. Dreyfus D.H., Randolph C.C. Characterization of an anaphylactoid reaction to omalizumab. Ann. Allergy Asthma Immunol. 2006; 96: 624-627.
55. Price K.S., Hamilton R.G. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007; 28: 313-319.